Nichols D, Dopico G A, Braun S, Imbeau S, Peters M E, Rankin J
Am J Med. 1979 Oct;67(4):631-7. doi: 10.1016/0002-9343(79)90246-8.
Pulmonary functions of patients with allergic bronchopulmonary aspergillosis were studied during an acute episode (n = 6); during a mean follow-up period of 44 months (range four months--14.8 years) (n = 16); and for any correlation between duration of ABPA and asthma with the total lung capacity (helium dilution), 1 second forced expiratory volume (FEV1), vital capacity, 1 second forced expiratory volume-forced vital capacity ratio (FEV1:FVC per cent) and diffusing capacity of carbon monoxide (DL:CO) (single breath) for the entire group (n = 22). All patients were treated with corticosteroids (intermittent or continuous) and bronchodilators. For the 16 patients, slopes using linear regression analysis were determined from the function as per cent predicted versus time in months from diagnosis and then analyzed for significance. Significant functional loss was shown in three of 16 patients for FEV1, two of 16 patients for vital capacity, one of 16 patients for FEV1:FVC per cent, none of 10 patients for DL:CO and one of 10 patients for total lung cital capacity, FEV1:FVC per cent and the duration of asthma or allergic bronchopulmonary aspergillosis was found by multiple regression analysis correcting for age and smoking (mean 4.24 years; range 0.3 to 14.8 years). Roentgenographic criteria and blood eosinophilia were used to define a "flare" of allergic bronchopulmonary aspergillosis. The six patients during a flare showed a significant reduction in total lung capacity (P less than 0.001), vital capacity (P less than 0.05), FEV1 (P less than 0.01) and DL:CO (P less than 0.001) which uniformly returned to baseline values during steroid therapy. The FEV1:FVC per cent remained unaltered. These findings, contrary to suggestions in the literature, indicate that in the majority of our patients there was no significant progressive functional deterioration after diagnosis. However, during acute episodes of allergic bronchopulmonary aspergillosis, transient reduction of volumes and DL:CO were uniformly present.
对变应性支气管肺曲霉病患者在急性发作期(n = 6)、平均随访44个月(范围4个月 - 14.8年)期间(n = 16)的肺功能进行了研究,并研究了变应性支气管肺曲霉病(ABPA)和哮喘病程与全组(n = 22)的肺总量(氦稀释法)、第1秒用力呼气量(FEV1)、肺活量、第1秒用力呼气量与用力肺活量比值(FEV1:FVC%)及一氧化碳弥散量(单次呼吸法,DL:CO)之间的相关性。所有患者均接受了皮质类固醇(间歇或持续使用)及支气管扩张剂治疗。对于16例患者,通过线性回归分析确定了从诊断开始以月为单位的预测百分比函数的斜率,然后进行显著性分析。16例患者中,3例FEV1、2例肺活量、1例FEV1:FVC%出现显著功能丧失,10例患者中DL:CO无显著功能丧失,10例患者中1例肺总量、FEV1:FVC%及哮喘或变应性支气管肺曲霉病病程经校正年龄和吸烟因素(平均4.24年;范围0.3至14.8年)的多元回归分析发现存在相关性。采用X线标准和血液嗜酸性粒细胞增多来定义变应性支气管肺曲霉病的“发作”。6例发作期患者的肺总量(P < 0.001)、肺活量(P < 0.05)、FEV1(P < 0.01)及DL:CO(P < 0.001)均显著降低,在类固醇治疗期间均恢复至基线值。FEV1:FVC%保持不变。与文献中的观点相反,这些发现表明,在我们的大多数患者中,诊断后没有明显的进行性功能恶化。然而,在变应性支气管肺曲霉病急性发作期,肺容积和DL:CO均出现短暂降低。